Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Regeneron Pharmaceuticals
(NQ:
REGN
)
962.49
-3.81 (-0.39%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Regeneron Pharmaceuticals
< Previous
1
2
3
4
5
Next >
Regeneron Provides Update on Biologics License Application for Odronextamab
March 25, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is a Leading Gainer in Friday Morning Trading
March 22, 2024
Via
Investor Brand Network
High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization
March 12, 2024
$250,000 top award goes to Achyuta Rajaram in the nation’s oldest and most prestigious Science, Technology, Engineering and Math (STEM) competition for high school seniors
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is a Leading Gainer in 2/20 Morning Trading
February 20, 2024
Via
Investor Brand Network
Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol
March 11, 2024
Approval extends treatment of Praluent to children aged 8 and older with heterozygous familial hypercholesterolemia (HeFH)
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet
March 08, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation
February 23, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review
February 21, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)
February 16, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron Announces Investor Conference Presentations
February 06, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
February 02, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Linvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma
February 02, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs
January 30, 2024
Regeneron to assume full development and commercialization rights for 2seventy bio’s preclinical and clinical stage cell therapy pipeline
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)
January 25, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards
January 24, 2024
Regeneron Science Talent Search Showcases Exceptional Young Leaders with Innovative Ideas in Science, Technology, Engineering and Math (STEM)
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) Sets New 52-Week High in Tuesday Session
January 23, 2024
Via
Investor Brand Network
Dupixent® (dupilumab) U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with Moderate-to-Severe Hand and Foot Involvement
January 16, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
3 health care stocks off to strong starts in 2024
January 10, 2024
With the bullish news flow lately, the market has taken a liking to health care stocks in recent weeks - including these three early 2024 gainers.
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Regeneron to Report Fourth Quarter and Full Year 2023 Financial and Operating Results and Host Conference Call and Webcast on February 2, 2024
January 05, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) Records 52-Week High Wednesday Morning
January 03, 2024
Via
Investor Brand Network
2 gene-editing stocks reshaping hereditary disease treatments
January 02, 2024
Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal
Via
MarketBeat
Regeneron Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
December 18, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron Named on Dow Jones Sustainability World Index for Fifth Consecutive Year
December 11, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Latest Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and Overall Maintenance of Patient-Reported Outcomes
December 10, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term Outcomes
December 10, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
3 biotech powerhouses poised to thrive amid sector rebound
December 08, 2023
If the newfound support and uptrend in the biotech sector last, as the new year quickly approaches, the biotech sector could shift from lagger to leader.
Via
MarketBeat
Topics
ETFs
Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma
December 07, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron to Share Progress of Novel Combination Therapies in Oncology at ESMO IO
December 07, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron to Host Investor Call and Webcast on December 14, 2023 to Provide Updates Across Its Hematology Portfolio
November 30, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease
November 27, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.